Key Points Preliminary results show 13 of 16 participants achieved at least a 50% reduction in their glucose infusion rate, exceeding the nine responders required…
November 13, 2026
November 13, 2026
Annovis Secures Buntanetap Crystal-Form Patent Through 2044 Ahead of Phase 3 Alzheimer’s Readout
Key Points Annovis received a U.S. patent covering buntanetap Form B, the crystalline form used in its ongoing Alzheimer’s and Parkinson’s studies. The patent covers…
November 09, 2026
CorMedix to Acquire Heron’s Drug Portfolio, Targets Up to $60 Million in Annual Savings
Key Points CorMedix will acquire substantially all of Heron’s assets, including four commercial medicines, for cash, shares and potential future payments. Upfront consideration was valued…
Key Points LifeMD’s affiliated pharmacy can directly dispense and ship Lilly’s Zepbound and Foundayo to eligible patients nationwide. Patients can purchase prescribed medicines through LifeMD…
November 04, 2026
NICE Expands Guidance for Rhythm Pharmaceuticals’ IMCIVREE to Include Adults With Bardet-Biedl Syndrome
Key Points NICE issued positive guidance extending IMCIVREE reimbursement eligibility to adults with genetically confirmed Bardet-Biedl syndrome, or BBS. The update enables eligible adults to…
Key Points Ardelyx has fully enrolled its Phase 3 ACCEL trial evaluating IBSRELA in adults with chronic idiopathic constipation, or CIC. The study compares twice-daily…
Key Points Allogene will deliver two invited presentations and a preclinical poster at the SITC Annual Meeting in Phoenix. Presentations will cover clinical experience from…
November 02, 2026
Actuate Receives U.S. Patent Allowance for Elraglusib Oral Tablets Ahead of Planned Trial
Key Points The USPTO issued a Notice of Allowance for claims covering oral tablet compositions of elraglusib, Actuate’s investigational GSK-3β inhibitor. The allowance includes the…
Key Points Nuvation Bio plans to add SIGMA study sites in the United Kingdom, France, Sweden, Germany, Italy and Spain. The pivotal Phase 3 trial…
Key Points Palisade Bio has dosed the first patient in ASCENTRA-UC, a Phase 2b study of once-daily oral PALI-2108. The randomized, placebo-controlled trial plans to…
Key Points Cumberland Pharmaceuticals plans to seek FDA approval for ifetroban to treat cardiomyopathy associated with Duchenne muscular dystrophy, or DMD. The FDA granted rolling…
October 23, 2026
BioLineRx and Hemispherian Report Encouraging GLIX1 Combination Results in Ovarian Cancer Models
Key Points GLIX1 enhanced the activity of three PARP inhibitors in laboratory studies of HR-proficient ovarian cancer cells. In a mouse model using patient-derived ovarian…